CDMO News news (page 2)

11 April 2018
Boehringer Ingelheim invests €65M in avian vaccines
A new 5,700 sq m facility in Lyon will boost avian vaccine production, creating 42 jobs. The environmentally friendly site will triple inactivated vaccine capacity by 2020.
29 November 2017
Saltigo Marks 50 Years of Innovation
ZeTO celebrates 50 years with a €60M expansion, adding new production lines and storage. Investments total €300M over 11 years, enhancing capacity and maintaining cutting-edge operations.
6 July 2017
Fresenius Kabi Expands Portugal Plant
Two new antibiotic production lines added, creating 80 jobs with a €17 million investment. The plant now spans 6,000 square meters and employs around 600 people.
16 June 2017
Takeda Completes New Manufacturing Facilities in Germany
The new facility in Oranienburg, costing 100M euros, will start by end-2017, creating 180 jobs. It enhances production for global markets, supported by German and Brandenburg subsidies.
31 May 2017
Takeda to Build New Production Facility in Ireland
The new facility will expand Takeda's Grange Castle site, creating 40 jobs and producing NINLARO® for global markets. Construction starts June 2017, with operations beginning in late 2018.
30 May 2017
Cambrex Expands Capacity and Adds Continuous Flow Technology in Sweden
The Karlskoga facility now has new reactors and a continuous flow unit, boosting production efficiency and flexibility for high purity intermediates, with completion expected by Q3 2017.

CDMO projects

A map displaying all CDMO projects in Europe

A map of CDMO projects that are planned or currently being executed.

Use chemXplore Analytics to power your research into CDMO.

Learn more

Scheduled completion

This chart shows how many CDMO projects in the European chemical industry are expected to be completed in the upcoming years.

Learn more

The right choices in the European chemical industry

Save time with chemXplore Analytics

← Previous

New construction vs expansion

Owners & Investors

Top 5 companies involved as owner and/or investor in current and planned CDMO projects:

Merck, Sandoz, Lonza, WACKER, Novo Nordisk, WCGC, WuXi, ACG, Arxada, and PCI Pharma Services.